China Resources Sanjiu Medical & Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
China Resources Sanjiu Medical & Pharmaceutical has been growing earnings at an average annual rate of 14.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 15% per year. China Resources Sanjiu Medical & Pharmaceutical's return on equity is 14.3%, and it has net margins of 13.2%.
Key information
14.9%
Earnings growth rate
14.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 15.0% |
| Return on equity | 14.3% |
| Net Margin | 13.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How China Resources Sanjiu Medical & Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 25,871 | 3,410 | 8,619 | 768 |
| 30 Jun 24 | 25,699 | 3,374 | 8,548 | 746 |
| 31 Mar 24 | 25,681 | 3,066 | 8,738 | 719 |
| 31 Dec 23 | 24,739 | 2,853 | 8,544 | 715 |
| 30 Sep 23 | 24,577 | 2,899 | 8,097 | 700 |
| 30 Jun 23 | 22,825 | 2,893 | 7,542 | 674 |
| 31 Mar 23 | 20,182 | 2,759 | 6,699 | 622 |
| 01 Jan 23 | 18,079 | 2,449 | 6,141 | 594 |
| 30 Sep 22 | 16,393 | 2,251 | 5,715 | 558 |
| 30 Jun 22 | 16,081 | 2,112 | 5,856 | 539 |
| 31 Mar 22 | 15,715 | 2,253 | 5,644 | 588 |
| 01 Jan 22 | 15,544 | 2,055 | 6,005 | 560 |
| 30 Sep 21 | 15,586 | 1,773 | 6,401 | 541 |
| 30 Jun 21 | 15,623 | 1,919 | 6,492 | 527 |
| 31 Mar 21 | 14,556 | 1,717 | 6,250 | 467 |
| 31 Dec 20 | 13,637 | 1,597 | 5,966 | 460 |
| 30 Sep 20 | 13,920 | 1,710 | 6,365 | 445 |
| 30 Jun 20 | 13,505 | 1,431 | 6,511 | 436 |
| 31 Mar 20 | 14,473 | 1,455 | 7,281 | 442 |
| 31 Dec 19 | 14,794 | 2,099 | 7,553 | 442 |
| 30 Sep 19 | 14,171 | 2,289 | 7,264 | 392 |
| 30 Jun 19 | 14,122 | 2,328 | 7,315 | 362 |
| 31 Mar 19 | 13,530 | 2,176 | 7,041 | 357 |
| 31 Dec 18 | 13,428 | 1,432 | 7,183 | 356 |
| 30 Sep 18 | 13,080 | 1,455 | 6,914 | 341 |
| 30 Jun 18 | 12,594 | 1,387 | 6,317 | 466 |
| 31 Mar 18 | 12,043 | 1,350 | 6,020 | 366 |
| 31 Dec 17 | 11,120 | 1,302 | 5,395 | 297 |
| 30 Sep 17 | 10,301 | 1,288 | 4,717 | 191 |
| 30 Jun 17 | 9,699 | 1,303 | 4,538 | 0 |
| 31 Mar 17 | 9,307 | 1,260 | 4,309 | 0 |
| 31 Dec 16 | 8,982 | 1,198 | 4,175 | 0 |
| 30 Sep 16 | 8,553 | 1,290 | 3,832 | 0 |
| 30 Jun 16 | 8,485 | 1,258 | 3,811 | 0 |
| 31 Mar 16 | 8,149 | 1,223 | 3,583 | 0 |
| 31 Dec 15 | 7,900 | 1,249 | 3,415 | 0 |
| 30 Sep 15 | 7,709 | 1,160 | 3,288 | 0 |
| 30 Jun 15 | 7,475 | 1,107 | 3,134 | 0 |
| 31 Mar 15 | 7,412 | 1,086 | 3,128 | 0 |
| 31 Dec 14 | 7,277 | 1,036 | 3,119 | 0 |
| 30 Sep 14 | 6,770 | 938 | 3,028 | 0 |
| 30 Jun 14 | 6,959 | 1,064 | 2,987 | 0 |
| 31 Mar 14 | 7,196 | 1,058 | 3,147 | 0 |
| 31 Dec 13 | 7,293 | 1,109 | 3,114 | 0 |
Quality Earnings: 000999 has high quality earnings.
Growing Profit Margin: 000999's current net profit margins (13.2%) are higher than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000999's earnings have grown by 14.9% per year over the past 5 years.
Accelerating Growth: 000999's earnings growth over the past year (17.6%) exceeds its 5-year average (14.9% per year).
Earnings vs Industry: 000999 earnings growth over the past year (17.6%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 000999's Return on Equity (14.3%) is considered low.